Cosmos Health Q3 Revenue Rises 38% to $17.1 Million

Reuters

2025/11/17

<a href="https://laohu8.com/S/COSM">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million

Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584062154"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584062154\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584062154?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584062154","market":"us","top_or_hot":-1,"title":"Cosmos Health Q3 Revenue Rises 38% to $17.1 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COSM\">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmos Health Q3 Revenue Rises 38% to $17.1 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmos Health Q3 Revenue Rises 38% to $17.1 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-17 22:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COSM\">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COSM","symbol_name":"COSMOS HEALTH INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL77V60m:1","article_id":"2584062154","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584062154","pubTimestamp":1763388988,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income  per share improved to $ from $ in Q3 2024, and adjusted EPS improved to $ from $. For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $ last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing fa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COSM":"COSMOS HEALTH INC","BK4175":"保健护理产品经销商"},"translate_title":"Cosmos Health第三季度收入增长38%至1710万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COSM":0.9},"content_text":"Cosmos Health Q3 Revenue Rises 38% to $17.1 Million\n    \n\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}